Brainstorm cell therapeutics partners with neals, the als association, and i am als to provide public access to biospecimens from nurown's phase 3 als study

Serum and cerebrospinal fluid samples from the phase 3 study of nurown® in als to be donated to the neals biorepository for use by the research community new york , jan. 10, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that bcli will donate biospecimens from nurown's placebo-controlled phase 3 als trial to the northeast amyotrophic lateral sclerosis consortium (neals) biorepository for use by the research community. the specimens are being submitted to the biorepository in connection with a $500,000 grant previously awarded to brainstorm by the als association and i am als, to support biomarker research.
BCLI Ratings Summary
BCLI Quant Ranking